<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04974723</url>
  </required_header>
  <id_info>
    <org_study_id>BA058-05-028</org_study_id>
    <nct_id>NCT04974723</nct_id>
  </id_info>
  <brief_title>&quot;Real-world Effectiveness and Cardiovascular Safety Study of Abaloparatide in Postmenopausal Women.&quot;</brief_title>
  <official_title>A Retrospective, Observational Cohort Study Evaluating the Effectiveness and Cardiovascular Safety of Abaloparatide in Postmenopausal Women New to Anabolic Therapies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radius Health, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PRA Health Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Radius Health, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the current study is to evaluate the real-world comparative effectiveness and&#xD;
      cardiovascular safety of ABL compared with TPTD during the 18 month period after treatment&#xD;
      initiation in propensity score (PS)-matched cohorts&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a retrospective observational cohort study using healthcare administrative claims&#xD;
      data from the USA.&#xD;
&#xD;
      This study will use anonymized patient claims data from PRA's Symphony Health Patient Source&#xD;
      Integrated Dataverse (IDV) database. Data are routinely collected in healthcare encounters&#xD;
      from all available healthcare sites (inpatient hospital, outpatient hospital, physician&#xD;
      office, pharmacy, etc.) for all types of provided services including specialty, preventive&#xD;
      care, and office-based treatments.&#xD;
&#xD;
      The patients for inclusion in the study analyses will be identified based on the prescribed&#xD;
      anabolic therapy filled (ABL or TPTD). The study intake period was chosen to coincide with&#xD;
      the date of the FDA approval of ABL in the USA.&#xD;
&#xD;
      This study will use anonymized patient claims data from the Symphony Health Patient Source&#xD;
      IDV database including the enhanced hospital data.&#xD;
&#xD;
      This retrospective cohort study is expected to include a total of 16,000 patients; 8000&#xD;
      patients per treatment cohort (ABL or TPTD).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 1, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Time to first incidence of nonvertebral fracture</measure>
    <time_frame>18 months</time_frame>
    <description>Time to the first incidence of nonvertebral fracture (hip, pelvis, shoulder, radius or ulna, wrist, femur, tibia or fibula, ankle) within the 18 months after treatment initiation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to the first incidence of a composite of nonfatal MI, nonfatal stroke, or in-hospital cardiovascular death</measure>
    <time_frame>18 months</time_frame>
    <description>Time to the first incidence of a composite of nonfatal MI, nonfatal stroke, or in-hospital cardiovascular death within the 18 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to the first incidence of a composite nonfatal MI, nonfatal stroke, heart failure or in-hospital cardiovascular death</measure>
    <time_frame>18 months</time_frame>
    <description>Time to the first incidence of a composite nonfatal MI, nonfatal stroke, heart failure or in-hospital cardiovascular death within the 18 months.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Time to first incidence of hip fracture</measure>
    <time_frame>18 months</time_frame>
    <description>Time to first incidence of hip fracture within 18 months.</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to first incidence of MI, stroke, in-hospital cardiovascular death or heart failure</measure>
    <time_frame>18 months</time_frame>
    <description>Time to first incidence of MI, stroke, in-hospital cardiovascular death or heart failure</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">16000</enrollment>
  <condition>Osteoporosis, Postmenopausal</condition>
  <arm_group>
    <arm_group_label>Patients Treated with Abaloparatide</arm_group_label>
    <description>Patients who filled ≥ 1 prescription for ABL (TYMLOS) as their index medication during the identification period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients Treated with Teriparatide</arm_group_label>
    <description>Patients who filled ≥ 1 prescription for TPTD (Forteo) as their index medication during the identification period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abaloparatide</intervention_name>
    <description>Abaloparatide subcutaneous (abaloparatide SC [ABL]; Tymlos®)</description>
    <arm_group_label>Patients Treated with Abaloparatide</arm_group_label>
    <other_name>Tymlos</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Teriparatide</intervention_name>
    <description>Teriparatide subcutaneous (TPTD; Forteo®)</description>
    <arm_group_label>Patients Treated with Teriparatide</arm_group_label>
    <other_name>Forteo</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study eligibility criteria are in alignment with the prescribing information in the FDA&#xD;
        approved labels for both ABL and TPTD and include women with postmenopausal osteoporosis.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women who are 50 years or older&#xD;
&#xD;
          -  ≥1 prescription fill for ABL or TPTD&#xD;
&#xD;
          -  ≥ 1 claim for medical or hospital visit and a pharmacy claim&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Paget's disease&#xD;
&#xD;
          -  Malignancy&#xD;
&#xD;
          -  Indicators of high disease burden and high risk of death&#xD;
&#xD;
          -  With prior index anabolic treatment&#xD;
&#xD;
          -  Switch to a different anabolic treatment after index&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Setareh A. Williams, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Radius Health, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Radius Health</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 18, 2021</study_first_submitted>
  <study_first_submitted_qc>July 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2021</study_first_posted>
  <last_update_submitted>August 13, 2021</last_update_submitted>
  <last_update_submitted_qc>August 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Osteoporosis, Postmenopausal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Teriparatide</mesh_term>
    <mesh_term>Abaloparatide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

